Sayeef Mirza

Prediction of non-relapse mortality (NRM) after allogeneic hematopoietic cell transplantation (HCT) is important, especially in older adults. Composite risk models using routine clinical and laboratory parameters have been developed and tested [1,2], but validation is needed. We evaluated a model for NRM in the real-world setting. We included consecutive transplants at the Moffitt Cancer Center 2014 to 2023 with pre-HCT CRP (N = 358). We excluded participants in CTN 1704 (N = 41).

In a conversation with CancerNetwork®, Leila Tchelebi, MD, a radiation oncologist at Northwell Health, highlighted the next steps for implementing a comprehensive multi-institutional cancer database to improve the personalize care of patients with cancer.

The FDA has granted fast track designation to NG-350A, an intravenously delivered T-SIGn® therapeutic, for the treatment of patients with mismatch repair-proficient (pMMR) locally advanced rectal cancer (LARC), according to a news release from the developer, Akamis Bio.1 The oncolytic immunotherapy is currently being assessed with chemotherapy in the phase 1b FORTRESS trial (NCT06459869) among patients with pMMR LARC.